HISTORY
Building a Better Tomorrow, Every Day
Every day we are innovating and evolving into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives.
2021
ACQUISITION
Alexion acquired by AstraZeneca. The AstraZeneca group focusing on rare diseases is created and named Alexion, AstraZeneca Rare Disease.
2020
ACQUISITION
Acquired Portola Pharmaceuticals, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders
ACQUISITION
Acquired Achillion Pharmaceuticals, the company that began development of two oral factor D inhibitors
2019
APPROVAL
Treatment approved for adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)
ABOUT aHUSAPPROVAL
First complement inhibitor approved for adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD)
ABOUT NMOSD![KIM](/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=375 375w,
/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=750 750w,
/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=768 768w,
/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=1024 1024w,
/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=1280 1280w,
/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=1536 1536w,
/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=2048 2048w,
/-/media/alexion_comredesign/images/realstories/nmosd/slide-5_kim_2560x1600.jpg?rev=2e422a458bd041848504d18372f7915a?mw=2560 2560w )
KIM
LIVING WITH NMOSD
PARTNERSHIP
Established partnerships with Caelum Biosciences, Zealand Pharma, and Affibody
2018
APPROVAL
Treatment approved for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
ABOUT PNH![Victor, diagnosed with PNH at 27 years old](/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=375 375w,
/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=750 750w,
/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=768 768w,
/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=1024 1024w,
/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=1280 1280w,
/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=1536 1536w,
/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=2048 2048w,
/-/media/alexion_comredesign/images/realstories/pnh/victor/victor-02-r.jpg?rev=57bbd01278614324b857681551fd4880?mw=2560 2560w )
VICTOR
LIVING WITH PNH
ACQUISITION
Acquired Syntimmune, the company that began development of a treatment for rare IgG-mediated diseases
ACQUISITION
Acquired Wilson Therapeutics, the company that began development of a treatment for Wilson Disease
COMPANY MILESTONE
Opened global headquarters in Boston
![Alexion's global headquarters opening ceremony in Boston](/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=375 375w,
/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=750 750w,
/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=768 768w,
/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=1024 1024w,
/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=1280 1280w,
/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=1536 1536w,
/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=2048 2048w,
/-/media/alexion_comredesign/images/non-patient-images/ribbon-tying-01-r.jpg?rev=338240e2f992473c81125d1deba06d65?mw=2560 2560w )
2017
2016
COMPANY MILESTONE
Opened the Center of Excellence in New Haven
2015
APPROVAL
First treatment approved for patients with lysosomal acid lipase deficiency (LAL-D)
ABOUT LAL-DAPPROVAL
First treatment approved for patients with hypophosphatasia (HPP)
ABOUT HPP![Evie, diagnosed with HPP at 2 weeks old, playing on a playground](/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=375 375w,
/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=750 750w,
/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=768 768w,
/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=1024 1024w,
/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=1280 1280w,
/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=1536 1536w,
/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=2048 2048w,
/-/media/alexion_comredesign/images/realstories/hpp/evie/evie-01-r.jpg?rev=923e84bdc1764da69982ddae6a29e0f5?mw=2560 2560w )
EVIE
LIVING WITH HPP
ACQUISITION
Acquired sebelipase alfa, a potential treatment for patients living with LAL-D
2012
ACQUISITION
Acquired asfostase alfa, a potential treatment for patients living with HPP
2011
APPROVAL
First treatment approved for patients with atypical hemolytic uremic syndrome (aHUS)
ABOUT aHUS2007
APPROVAL
First treatment approved for patients with paroxysmal nocturnal hemoglobinuria (PNH)
ABOUT PNH![Joe, diagnosed with PNH at 24 years old, training for mixed martial arts](/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=375 375w,
/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=750 750w,
/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=768 768w,
/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=1024 1024w,
/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=1280 1280w,
/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=1536 1536w,
/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=2048 2048w,
/-/media/alexion_comredesign/images/realstories/pnh/joe/joe-02-r.jpg?rev=402818e3079e4ca59550b5c6222b7971?mw=2560 2560w )
JOE
LIVING WITH PNH
1996
COMPANY MILESTONE
Alexion goes public with ticker ALXN
1992
COMPANY MILESTONE
Alexion founded in New Haven, CT
![Alexion's original location in New Haven, CT](/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=375 375w,
/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=750 750w,
/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=768 768w,
/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=1024 1024w,
/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=1280 1280w,
/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=1536 1536w,
/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=2048 2048w,
/-/media/alexion_comredesign/images/non-patient-images/science-park-gate-01-r.jpg?rev=10fe654c9c084562b86f07f49f6b7a81?mw=2560 2560w )
Related Topics
![Jill, diagnosed with aHUS at 28 years old, with her daughter](/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=375 375w,
/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=750 750w,
/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=768 768w,
/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=1024 1024w,
/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=1280 1280w,
/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=1536 1536w,
/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=2048 2048w,
/-/media/alexion_comredesign/images/realstories/ahus/jill/jill-02-f.jpg?rev=cef5d7c245624c4fbc3e1c04d6362607?mw=2560 2560w )
Help is out there and we’re not alone anymore.”JILL LIVING WITH aHUS